Roche Holding AG
RHHBFOTCHealthcare● Active
$425.51
+$17.43(+4.27%)
Market Cap$338.7B
P/E Ratio—
52W High$514.08
52W Low$296.1
Roche Holding AG (RHHBF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RHHBF · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Jan 29, 2026EPS Actual
$10.56
Est. $10.83 · -2.5%
Revenue
$38.56B
Est. $39.22B · -1.7%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Jan 29, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
RHHBF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | $12.74 | — | — | — | $38.53B | — |
| ▼ Q1 FY2026 | Jan 29, 2026 | $10.83 | $10.56 | -2.5% | $38.56B | $39.22B | -1.7% |
| ▼ Q3 FY2025 | Jul 24, 2025 | $13.18 | $5.81 | -55.9% | $20.04B | $15.02B | +33.4% |
| ▼ Q1 FY2025 | Jan 30, 2025 | $9.25 | $2.77 | -70.0% | $34.84B | $33.90B | +2.8% |
| ▼ Q4 FY2024 | Oct 23, 2024 | $10.42 | $8.71 | -16.4% | $34.33B | $32.94B | +4.2% |
| ▼ Q2 FY2024 | Apr 26, 2024 | $10.07 | $6.34 | -37.0% | $33.82B | $34.75B | -2.7% |
| ▼ Q4 FY2023 | Nov 29, 2023 | $11.62 | $9.90 | -14.8% | $33.20B | $33.83B | -1.9% |
| ▼ Q1 FY2023 | Feb 2, 2023 | $9.49 | $5.26 | -44.6% | $33.50B | $33.47B | +0.1% |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
$12.74
EPS Surpr.
—
Revenue
—
Q1 FY2026
Jan 29, 2026Miss
EPS Actual
$10.56
EPS Est.
$10.83
EPS Surpr.
-2.5%
Revenue
$38.56B
Q3 FY2025
Jul 24, 2025Miss
EPS Actual
$5.81
EPS Est.
$13.18
EPS Surpr.
-55.9%
Revenue
$20.04B
Q1 FY2025
Jan 30, 2025Miss
EPS Actual
$2.77
EPS Est.
$9.25
EPS Surpr.
-70.0%
Revenue
$34.84B
Q4 FY2024
Oct 23, 2024Miss
EPS Actual
$8.71
EPS Est.
$10.42
EPS Surpr.
-16.4%
Revenue
$34.33B
Q2 FY2024
Apr 26, 2024Miss
EPS Actual
$6.34
EPS Est.
$10.07
EPS Surpr.
-37.0%
Revenue
$33.82B
Q4 FY2023
Nov 29, 2023Miss
EPS Actual
$9.90
EPS Est.
$11.62
EPS Surpr.
-14.8%
Revenue
$33.20B
Q1 FY2023
Feb 2, 2023Miss
EPS Actual
$5.26
EPS Est.
$9.49
EPS Surpr.
-44.6%
Revenue
$33.50B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $15.4B | $15.5B | $15.7B | 2 |
| Q2 FY2026 | $15.5B | $15.6B | $15.7B | 2 |
| Q1 FY2026 | $14.7B | $14.7B | $14.7B | 2 |
| Q4 FY2025 | $14.7B | $14.9B | $15.3B | 4 |
| Q3 FY2025 | $14.8B | $15.0B | $15.2B | 4 |
| Q2 FY2025 | $15.8B | $15.9B | $16.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Jan 29, 2026 | -2.5% | $447.50 | $440.00 | -1.68% |
| ▼ Q3 FY2025 | Jul 24, 2025 | -55.9% | $347.00 | $364.50 | +5.04% |
| ▼ Q1 FY2025 | Jan 30, 2025 | -70.0% | $326.50 | $331.66 | +1.58% |
| ▼ Q4 FY2024 | Oct 23, 2024 | -16.4% | $350.00 | $351.00 | +0.29% |
| ▼ Q2 FY2024 | Apr 26, 2024 | -37.0% | $273.40 | $255.60 | -6.51% |
| ▼ Q4 FY2023 | Nov 29, 2023 | -14.8% | $280.25 | $285.50 | +1.87% |
| ▼ Q1 FY2023 | Feb 2, 2023 | -44.6% | $343.07 | $347.00 | +1.15% |
| ▼ Q3 FY2022 | Jul 21, 2022 | -4.7% | $392.04 | $416.50 | +6.24% |
Q1 FY2026-1.68%
Report Date
Jan 29, 2026
EPS Beat/Miss
-2.5%
Price Before
$447.50
Price After
$440.00
Q3 FY2025+5.04%
Report Date
Jul 24, 2025
EPS Beat/Miss
-55.9%
Price Before
$347.00
Price After
$364.50
Q1 FY2025+1.58%
Report Date
Jan 30, 2025
EPS Beat/Miss
-70.0%
Price Before
$326.50
Price After
$331.66
Q4 FY2024+0.29%
Report Date
Oct 23, 2024
EPS Beat/Miss
-16.4%
Price Before
$350.00
Price After
$351.00
Q2 FY2024-6.51%
Report Date
Apr 26, 2024
EPS Beat/Miss
-37.0%
Price Before
$273.40
Price After
$255.60
Q4 FY2023+1.87%
Report Date
Nov 29, 2023
EPS Beat/Miss
-14.8%
Price Before
$280.25
Price After
$285.50
Q1 FY2023+1.15%
Report Date
Feb 2, 2023
EPS Beat/Miss
-44.6%
Price Before
$343.07
Price After
$347.00
Q3 FY2022+6.24%
Report Date
Jul 21, 2022
EPS Beat/Miss
-4.7%
Price Before
$392.04
Price After
$416.50
Avg Miss Reaction+1.00%
Beat Rate0 / 8 quarters
Largest Move-6.51% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RHHBF ends December
Roche Holding AG (RHHBF) most recently reported earnings on January 29, 2026 for Q1 FY2026, posting EPS of $10.56 — missing the analyst consensus of $10.83 by -2.5%. The next RHHBF earnings date is expected around September 1, 2026.
Each quarter, investors track RHHBF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RHHBF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RHHBF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RHHBF earnings · 5 questionsRoche Holding AG's next earnings report is expected around September 1, 2026. RHHBF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RHHBF historically reports after market close (AMC).
RHHBF earnings datewhen is RHHBF earningsRHHBF next earnings datewhen does RHHBF report earningsRHHBF earnings calendar
▸ Source: FMP · Roche Holding AG SEC filings · US GAAP · Roche Holding AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026